The influence of somatostatin analogues on the uptake of neuroendocrine tumors in somatostatin receptor-specific PET [28] and of antihormonal treatment on PSMA uptake in prostate cancer cells [29,30] are currently under investigation. Here, FOLH1 is linked to prostate cancer.